Patient P-01688
Synthetic patientNBL-101 · Day 113 · 55–64 · F · baseline S01Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Improving
Inflammatory state
Deteriorating
Nutritional resilience
Improving
Discontinuation risk
47%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S01
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −18% vs expected — Dietary Support Protocol NP-02
- Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 55 GI-04 recommended — GI Support Protocol GI-04
- Day 56 Patient accepted — Started GI-04 in the companion
- Day 64 GI symptom burden −22% vs expected — GI Support Protocol GI-04
- Day 70 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 44.
Primary contributors, last 14 days
- GI instability-6
- Inflammatory activity+6
- Nutritional resilience+6
- Toxicity-5
- Treatment adherence-4
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −18%
- GI Support Protocol GI-04Day 55Result: symptom burden −22%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
75%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion41.3/100
stable · -1.6 vs previous 14 d
Toxicity
Blood36.6/100
stable · -0.1 vs previous 14 d
Sleep quality
Wearable35.7/100
improving · +6.2 vs previous 14 d
Energy level
Daily log4.3/10
improving · +0.1 vs previous 14 d
Stress level
Daily log5.6/10
stable · +0.1 vs previous 14 d
Steps
Wearable3,753
stable · -9 vs previous 14 d
Adherence
Companion49.5 %
improving · +3.1 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 37 from the failing basin, 52 from restoration.
Good elements to keep
- GI Support Protocol GI-04intervention · steering +36.1
- Dietary Support Protocol NP-02intervention · steering +28.4
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- Low butyrate capacityhidden · steering -17.5
- Dietary fat loadperturbation · steering -12.6
- FUT2 non-secretorhidden · steering -10.6
- Insoluble fibreperturbation · steering -8.1
- Dietary fat loaddetractor · GI +6.5 next day
- Histamine loaddetractor · GI +4.5 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+6.5detractor · 95%
- Histamine load+4.5detractor · 95%
- Insoluble fibre+4.5detractor · 95%
- Alcohol+4detractor · 95%
- Simple carbohydrates+3.1no signal · 54%
- Spicy / capsaicin+0.7no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 47
- WearableHRV 26 ms, trending down
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↑20
- Wearable3,753 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.8 · butyrate capacity 29/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 25 ms
- Sleep
- 5.8 h
- Steps
- 2,787
- Resting HR
- 73 bpm
Daily log: GI score 41, nutritional resilience 48, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01518 | 52% | S14 | GI-04 | improved | 40 |
| P-01431 | 51% | S14 | GI-04 | improved | 41 |
| P-01611 | 50% | S14 | GI-04 | improved | 44 |
| P-01556 | 49% | S14 | GI-04 | improved | 44 |
| P-01330 | 48% | S14 | GI-04 | improved | 47 |
| P-01400 | 48% | S17 | GI-04 | improved | 51 |
| P-01667 | 48% | S10 | GI-04 | improved | 49 |
| P-01336 | 47% | S03 | GI-04 | improved | 51 |
| P-01349 | 47% | S14 | GI-04 | improved | 38 |
| P-01534 | 47% | S14 | GI-04 | improved | 50 |
| P-01705 | 47% | S14 | GI-04 | improved | 39 |
| P-01429 | 46% | S09 | GI-04 | improved | 45 |